Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board

Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patie...

Full description

Bibliographic Details
Main Authors:	M. V. Shestakova, V. A. Dobronravov, A. S. Ametov, M. B. Antsiferov, M. M. Batyushin, I. N. Bobkova, G. R. Galstyan, T. Y. Demidova, V. V. Klimontov, A. M. Mkrtumyan, N. A. Petunina, E. I. Prokopenko, N. V. Chebotareva, M. S. Shamkhalova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2023-11-01
Series:	Сахарный диабет
Subjects:	finerenone non-steroidal mineralocorticoid receptor antagonist diabetes mellitus chronic kidney disease
Online Access:	https://www.dia-endojournals.ru/jour/article/view/13020

Similar Items

A Trial of Finerenone in a Patient with Primary Aldosteronism
by: Sandra Karanović Štambuk
Published: (2024-09-01)

Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023-01-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

Role of L‐type Ca2+‐channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue
by: Francesca Schinzari, et al.
Published: (2024-09-01)

Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies
by: Franz Schaefer, et al.
Published: (2024-03-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)

Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
by: Francesco Piccirillo, et al.
Published: (2023-05-01)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
by: Ruolin Lv, et al.
Published: (2023-02-01)

Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review
by: Vladimir V. Salukhov, et al.
Published: (2023-04-01)

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
by: Sylvia E. Rosas, et al.
Published: (2023-10-01)

Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases
by: Wenmin Chen, et al.
Published: (2023-12-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
by: Shaikh A, et al.
Published: (2022-07-01)

Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
by: Nejc Piko, et al.
Published: (2024-03-01)

Potassium management with finerenone: Practical aspects
by: Christoph Wanner, et al.
Published: (2022-11-01)

Finerenone in the management of diabetes kidney disease
by: Parijat De, et al.
Published: (2025-02-01)

Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research
by: Argen Mamazhakypov, et al.
Published: (2023-01-01)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
by: Nicholas Chiu, et al.
Published: (2022-04-01)

Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use
by: Yu. Sh. Khalimov, et al.
Published: (2024-03-01)

Finerenone Ameliorates High Glucose-Induced Podocytes Epithelial-Mesenchymal Transition Through the Regulation of Krüppel-Like Factor 5 in Diabetic Nephropathy
by: Shu J, et al.
Published: (2025-02-01)

The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
by: M. B. Antsiferov, et al.
Published: (2023-05-01)

A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
by: I. S. Khalimov, et al.
Published: (2025-01-01)

Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
by: Lan Yao, et al.
Published: (2023-12-01)

Primary aldosteronism with postoperative elevation of aldosterone treated effectively by finerenone: A case report
by: Cai‐Guo Yu, et al.
Published: (2024-09-01)

Cardiorenal benefits of finerenone: protecting kidney and heart
by: José R. González-Juanatey, et al.
Published: (2023-12-01)

Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
by: Jingying Zhou, et al.
Published: (2024-12-01)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
by: Tao Jin, et al.
Published: (2023-04-01)

Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms
by: Jing Wang, et al.
Published: (2024-09-01)

Efficacy of finerenone in reducing heart failure outcomes in patients with history of heart failure: A meta-analysis of randomized controlled trials
by: Vikash Jaiswal, et al.
Published: (2024-12-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease
by: Akira Mima, et al.
Published: (2024-06-01)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
by: Dimitrios Patoulias, et al.
Published: (2022-02-01)

Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease
by: Mohamad Hanouneh, et al.
Published: (2024-06-01)

Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
by: M. V. Shestakova, et al.
Published: (2021-07-01)

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
by: Haitao Zhang, et al.
Published: (2023-08-01)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
by: Raquel González-Blázquez, et al.
Published: (2018-10-01)

Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension
by: O. B. Kuzmin, et al.
Published: (2024-10-01)

The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
by: Mustafa Arici, et al.
Published: (2024-06-01)

Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis
by: Xinrui Jiang, et al.
Published: (2022-06-01)